|
schizophrenia |
59 |
|
first-episode psychosis |
40 |
|
negative symptoms |
38 |
|
covid-19 |
35 |
|
depression |
35 |
|
youth mental health |
34 |
|
psychosis |
30 |
|
psychotic disorders |
29 |
|
early psychosis |
27 |
|
stigma |
24 |
|
functioning |
23 |
|
predictors |
23 |
|
relapse |
23 |
|
first-episode schizophrenia |
22 |
|
mental health |
22 |
|
cognitive impairment |
21 |
|
physical activity |
21 |
|
social unrest |
21 |
|
duration of untreated psychosis |
19 |
|
anxiety |
17 |
|
epidemiology |
17 |
|
risk factors |
17 |
|
rumination |
17 |
|
antipsychotics |
16 |
|
delusional disorder |
16 |
|
depressive symptoms |
16 |
|
early intervention |
16 |
|
first episode |
16 |
|
functional outcome |
16 |
|
post-traumatic stress disorder |
16 |
|
prevalence |
16 |
|
adolescents |
15 |
|
amotivation |
15 |
|
insight |
15 |
|
medical sciences |
15 |
|
psychiatry and neurology |
15 |
|
quality of life |
15 |
|
stress |
15 |
|
avolition |
14 |
|
first-episode |
14 |
|
psychopathology |
14 |
|
remission |
14 |
|
executive function |
13 |
|
medication adherence |
13 |
|
premorbid adjustment |
13 |
|
validation study |
13 |
|
assessment |
12 |
|
caregivers |
12 |
|
cognition |
12 |
|
cost-effectiveness |
12 |
|
evaluation |
12 |
|
experience sampling method |
12 |
|
momentary positive affect |
12 |
|
adherence |
11 |
|
age of onset |
11 |
|
diminished expression |
11 |
|
employment |
11 |
|
long-term outcomes |
11 |
|
longitudinal follow-up |
11 |
|
pattern glare |
11 |
|
perceptual distortions |
11 |
|
processing speed |
11 |
|
prospective follow-up |
11 |
|
young people |
11 |
|
youth |
11 |
|
cognitive functions |
10 |
|
community-based intervention |
10 |
|
disengagement |
10 |
|
double blind |
10 |
|
f-dopa |
10 |
|
maintenance |
10 |
|
mindfulness |
10 |
|
positron emission tomography |
10 |
|
randomized controlled trial |
10 |
|
relapse prevention |
10 |
|
sex difference |
10 |
|
striatal dopamine capacity synthesis |
10 |
|
treatment adherence |
10 |
|
youth-friendly |
10 |
|
early medical intervention - methods - trends |
9 |
|
hallucination |
9 |
|
health education - methods |
9 |
|
hong kong |
9 |
|
ideas of reference |
9 |
|
internalized stigma |
9 |
|
intervention |
9 |
|
life events |
9 |
|
mental health services - trends |
9 |
|
motivational deficits |
9 |
|
omicron |
9 |
|
program development |
9 |
|
psychotic disorders - therapy |
9 |
|
psychotic-like experiences |
9 |
|
public stigma |
9 |
|
smartphone overuse |
9 |
|
traumatic events |
9 |
|
treatment outcome |
9 |
|
cluster analysis |
8 |
|
corpus striatum |
8 |
|
discontinuation |
8 |
|
dopamine |
8 |
|
dose-dependent effect |
8 |
|
eye-gaze perception |
8 |
|
growth mixture modeling |
8 |
|
latent class analysis |
8 |
|
long-term outcome |
8 |
|
maintenance treatment |
8 |
|
mass screening |
8 |
|
mentalization |
8 |
|
pandemic |
8 |
|
persistent psychotic experience |
8 |
|
prospective study |
8 |
|
ptsd symptoms |
8 |
|
raclopride |
8 |
|
resilience |
8 |
|
self-discrepancy |
8 |
|
self-reference |
8 |
|
self-stigma |
8 |
|
trauma exposure |
8 |
|
anti-stigma campaigns |
7 |
|
asia |
7 |
|
asian continental ancestry group |
7 |
|
chinese |
7 |
|
community |
7 |
|
duration of untreated psychosis (dup) |
7 |
|
effort-cost computation |
7 |
|
extended early intervention |
7 |
|
first episode psychosis |
7 |
|
first-episode schizophrenia spectrum disorder |
7 |
|
functional remission |
7 |
|
help-seeking |
7 |
|
help‐seeking |
7 |
|
hospitalization |
7 |
|
human |
7 |
|
illness disclosure |
7 |
|
late-onset psychosis |
7 |
|
latent class growth analysis |
7 |
|
letter |
7 |
|
long-term follow-up |
7 |
|
longitudinal course |
7 |
|
maternal age |
7 |
|
mental health literacy |
7 |
|
meta-analysis |
7 |
|
motivational impairment |
7 |
|
network analysis |
7 |
|
neurobiology |
7 |
|
neuropsychology |
7 |
|
paternal age |
7 |
|
pathways |
7 |
|
prediction |
7 |
|
psychosocial |
7 |
|
ptsd symptoms, women mental health |
7 |
|
real-world functioning |
7 |
|
rehospitalization |
7 |
|
sociodemographic correlates |
7 |
|
stressful life event |
7 |
|
symptomatology |
7 |
|
treatment delay |
7 |
|
violence |
7 |
|
adults |
6 |
|
affective psychoses |
6 |
|
antipsychotic |
6 |
|
anxiety disorders |
6 |
|
app |
6 |
|
attitude |
6 |
|
at‐risk mental state |
6 |
|
balloon analogue risk task |
6 |
|
category fluency |
6 |
|
chinese zodiac signs |
6 |
|
chizophrenia |
6 |
|
clinical high‐risk |
6 |
|
clinical predictors |
6 |
|
clozapine |
6 |
|
clozapine-resistant schizophrenia |
6 |
|
cognitive clusters |
6 |
|
cognitive flexibility |
6 |
|
cognitive function |
6 |
|
cognitive heterogeneity |
6 |
|
cognitive insights |
6 |
|
communityolder |
6 |
|
concepts |
6 |
|
cultural sensitivity |
6 |
|
culture |
6 |
|
delivery of health care - standards |
6 |
|
depressive mood |
6 |
|
development |
6 |
|
digit symbol test |
6 |
|
digital technologies |
6 |
|
early diagnosis |
6 |
|
early intervention service |
6 |
|
early medical intervention - standards |
6 |
|
effort allocation |
6 |
|
effort discounting |
6 |
|
effort-based decision-making |
6 |
|
ethnic minority |
6 |
|
exercise |
6 |
|
female |
6 |
|
fitmind |
6 |
|
fractionation |
6 |
|
global functioning |
6 |
|
guideline |
6 |
|
health surveys |
6 |
|
history |
6 |
|
illness attributional belief |
6 |
|
immersive |
6 |
|
incidence |
6 |
|
internal feed-forward |
6 |
|
interview, psychological |
6 |
|
labelling |
6 |
|
lifetime prevalence |
6 |
|
long-term trajectories |
6 |
|
longitudinal negative symptoms |
6 |
|
memory |
6 |
|
mental disorders / epidemiology |
6 |
|
mental health services |
6 |
|
mental health services - standards |
6 |
|
meta analysis |
6 |
|
mhealth |
6 |
|
mindfulness-based intervention |
6 |
|
negative treatment attitude |
6 |
|
neurocognition |
6 |
|
outcomes |
6 |
|
passivity experiences |
6 |
|
path analysis |
6 |
|
pilot |
6 |
|
pilot trial |
6 |
|
population surveys |
6 |
|
predictive validity |
6 |
|
primary negative symptoms |
6 |
|
priority journal |
6 |
|
prodrome |
6 |
|
psychiatric comorbidity |
6 |
|
psychoeducation |
6 |
|
recommendation |
6 |
|
reliability |
6 |
|
review |
6 |
|
risk aversion |
6 |
|
risk taking |
6 |
|
risky–gains task |
6 |
|
schizophrenia-spectrum disorder |
6 |
|
self-monitoring |
6 |
|
semantic |
6 |
|
sex differences |
6 |
|
smartphone |
6 |
|
social functioning |
6 |
|
subjective quality of life |
6 |
|
suicidal ideation |
6 |
|
switching |
6 |
|
symptomatic remission |
6 |
|
systematic review |
6 |
|
treatment |
6 |
|
treatment resistant schizophrenia |
6 |
|
treatment-resistant schizophrenia |
6 |
|
ultra-high risk |
6 |
|
validation |
6 |
|
virtual reality |
6 |
|
vocational outcome |
6 |
|
vr |
6 |
|
web-based |
6 |
|
working memory |
6 |
|
10-year follow-up |
5 |
|
10-year outcomes |
5 |
|
1st episode |
5 |
|
adolescent onset |
5 |
|
adult onset |
5 |
|
affiliate stigma |
5 |
|
aggressive behavior |
5 |
|
alogia |
5 |
|
anhedonia |
5 |
|
asian network for early psychosis |
5 |
|
asociality |
5 |
|
at-risk mental state |
5 |
|
auditory cortex |
5 |
|
auditory hallucination |
5 |
|
behavior |
5 |
|
blunted affect |
5 |
|
brain size |
5 |
|
caregiver |
5 |
|
caregivers’ distress |
5 |
|
chinese population |
5 |
|
clinical high-risk |
5 |
|
compliance |
5 |
|
cortical thickness (brain) |
5 |
|
dangerous |
5 |
|
dementia |
5 |
|
discrimination |
5 |
|
disease severity |
5 |
|
drug knowledge |
5 |
|
face concern |
5 |
|
financial deprivation |
5 |
|
first psychosis |
5 |
|
first-episode mania |
5 |
|
firstepisode psychosis |
5 |
|
first‐episode psychosis |
5 |
|
formal thought disorder |
5 |
|
gender differences |
5 |
|
gender effect |
5 |
|
general self-efficacy |
5 |
|
genetic high-risk |
5 |
|
glucose supplement |
5 |
|
hopelessness |
5 |
|
knowledge about psychosis |
5 |
|
knowledge of medication |
5 |
|
language |
5 |
|
language disorganization |
5 |
|
learned irrelevance |
5 |
|
media |
5 |
|
media report violent |
5 |
|
mediators |
5 |
|
medication |
5 |
|
medication discontinuation |
5 |
|
medication knowledge |
5 |
|
meta-aggregation |
5 |
|
metabolic screening |
5 |
|
metabolic syndrome |
5 |
|
neurocognitive impairment |
5 |
|
neuroleptic agent |
5 |
|
newspapers |
5 |
|
patient demographics |
5 |
|
perceived public stigma |
5 |
|
positive symptoms |
5 |
|
program |
5 |
|
psychiatry |
5 |
|
psychological symptoms |
5 |
|
psychotic disorder |
5 |
|
psychotic-like experience |
5 |
|
qualitative |
5 |
|
qualitative systematic review |
5 |
|
recovery |
5 |
|
schizophrenia-spectrum disorders |
5 |
|
school-based programme |
5 |
|
selective attention |
5 |
|
social contact |
5 |
|
social stigma |
5 |
|
stereotyping |
5 |
|
stigma reduction |
5 |
|
suicidal behavior |
5 |
|
suicide attempt |
5 |
|
syntax |
5 |
|
trial |
5 |
|
video |
5 |
|
youth and adult |
5 |
|
antiepileptics |
3 |
|
cbt |
3 |
|
cognitive behavioural therapy |
3 |
|
electronic health records |
3 |
|
family therapy |
3 |
|
lithium |
3 |
|
mind-body intervention |
3 |
|
prospective memory |
3 |
|
tai chi |
3 |
|
within-individual comparison |
3 |
|
yoga |
3 |
|
adult |
2 |
|
bipolar disorder |
2 |
|
brain |
2 |
|
connectome analysis |
2 |
|
diffusion weighted mri |
2 |
|
gender |
2 |
|
impulse control |
2 |
|
mri |
2 |
|
network |
2 |
|
nutrition-based intervention |
2 |
|
older patients |
2 |
|
prescription pattern |
2 |
|
prescription patterns |
2 |
|
retrospective memory |
2 |
|
willpower |
2 |
|
abdominal fat |
1 |
|
adjunctive |
1 |
|
adolescent |
1 |
|
adverse effects |
1 |
|
age factors |
1 |
|
aged |
1 |
|
alzheimer’s disease |
1 |
|
anorexia nervosa |
1 |
|
anthropometry |
1 |
|
anticholinergic |
1 |
|
antidepressant |
1 |
|
antimanic agents - administration and dosage - therapeutic use |
1 |
|
antipsychotic agents |
1 |
|
antipsychotic agents - administration & dosage - adverse effects - therapeutic use |
1 |
|
antipsychotic agents - administration and dosage - therapeutic use |
1 |
|
antipsychotic agents - adverse effects |
1 |
|
antipsychotic agents - adverse effects - therapeutic use |
1 |
|
antipsychotic agents - therapeutic use |
1 |
|
antipsychotic drugs |
1 |
|
antipsychotic polypharmacy |
1 |
|
asian |
1 |
|
awareness |
1 |
|
benzodiazepines |
1 |
|
benzodiazepines - administration & dosage - adverse effects - therapeutic use |
1 |
|
body fat |
1 |
|
body mass |
1 |
|
body mass index |
1 |
|
body weight - drug effects |
1 |
|
breast neoplasms |
1 |
|
brief psychiatric rating scale |
1 |
|
bulimia nervosa |
1 |
|
burden |
1 |
|
catatonia |
1 |
|
charcoal |
1 |
|
chi-square distribution |
1 |
|
china |
1 |
|
chlorpromazine |
1 |
|
cholinergic antagonists - adverse effects - therapeutic use |
1 |
|
clinical |
1 |
|
clozapine - adverse effects - therapeutic use |
1 |
|
community living skills |
1 |
|
comorbidity |
1 |
|
conversion disorder |
1 |
|
cost of illness |
1 |
|
cross-sectional studies |
1 |
|
diagnosis |
1 |
|
diagnostic and statistical manual of mental disorders |
1 |
|
dissociative disorders |
1 |
|
drug monitoring |
1 |
|
drug prescriptions - statistics & numerical data |
1 |
|
drug resistance - drug effects |
1 |
|
drug therapy, combination |
1 |
|
drug therapy, combination - adverse effects |
1 |
|
drug utilization - statistics & numerical data |
1 |
|
dyskinesia, drug-induced - epidemiology - ethnology - etiology |
1 |
|
dyslipidemia |
1 |
|
eating disorders |
1 |
|
electroconvulsive therapy |
1 |
|
epidemiologic studies |
1 |
|
ethnicity |
1 |
|
euthymia |
1 |
|
extrapyramidal side effects |
1 |
|
genitalia, male |
1 |
|
hallucinations |
1 |
|
haloperidol |
1 |
|
high dose |
1 |
|
humans |
1 |
|
hysteria |
1 |
|
inpatients |
1 |
|
intelligence |
1 |
|
latent class analysis (lca) |
1 |
|
logistic models |
1 |
|
low doses |
1 |
|
major depressive disorder |
1 |
|
male |
1 |
|
marital status |
1 |
|
measurement |
1 |
|
medical |
1 |
|
memory disorders - diagnosis - etiology |
1 |
|
memory, episodic |
1 |
|
mental illness |
1 |
|
mental patient |
1 |
|
middle aged |
1 |
|
mood stabilizers |
1 |
|
morbidity |
1 |
|
mortality |
1 |
|
movement disorders - physiopathology |
1 |
|
multiple sclerosis |
1 |
|
neoplasm metastasis |
1 |
|
neuropsychological test |
1 |
|
neuropsychological tests |
1 |
|
obesity |
1 |
|
olanzapine |
1 |
|
overweight - chemically induced - complications |
1 |
|
paranoid |
1 |
|
parkinson’s disease |
1 |
|
patient dropouts |
1 |
|
physician's practice patterns |
1 |
|
physician's practice patterns - statistics & numerical data - trends |
1 |
|
physician's practice patterns - trends |
1 |
|
pneumoconiosis |
1 |
|
polytherapy |
1 |
|
practice guidelines as topic |
1 |
|
prescription |
1 |
|
prospective design |
1 |
|
prospective studies |
1 |
|
psychiatric |
1 |
|
psychiatric status rating scales |
1 |
|
psychometrics |
1 |
|
psychotropic drugs |
1 |
|
psychotropic drugs - administration & dosage - adverse effects - therapeutic use |
1 |
|
pulmonary disease, chronic obstructive |
1 |
|
qtc prolongation |
1 |
|
quality of life - psychology |
1 |
|
questionnaires |
1 |
|
recurrence - prevention & control |
1 |
|
regression analysis |
1 |
|
residence characteristics |
1 |
|
risperidone |
1 |
|
risperidone - administration & dosage - adverse effects - therapeutic use |
1 |
|
schizophrenia - complications |
1 |
|
schizophrenia - complications - drug therapy |
1 |
|
schizophrenia - complications - drug therapy - physiopathology - prevention & control |
1 |
|
schizophrenia - diagnosis |
1 |
|
schizophrenia - diagnosis - drug therapy |
1 |
|
schizophrenia - diagnosis - drug therapy - pathology - physiopathology |
1 |
|
schizophrenia - drug therapy |
1 |
|
schizophrenia - drug therapy - physiopathology |
1 |
|
schizophrenia - epidemiology |
1 |
|
schizophrenia, paranoid - drug therapy - psychology |
1 |
|
schizophrenic psychology |
1 |
|
self-injurious behavior |
1 |
|
sex characteristics |
1 |
|
sex factors |
1 |
|
sexual dysfunction |
1 |
|
side effect |
1 |
|
smoking |
1 |
|
smoking - epidemiology |
1 |
|
social adjustment |
1 |
|
socioeconomic factors |
1 |
|
statistics as topic |
1 |
|
statistics, nonparametric |
1 |
|
subtype |
1 |
|
suicide |
1 |
|
tardive dyskinesia |
1 |
|
thinness - chemically induced - complications |
1 |
|
time factors |
1 |
|
treatment duration |
1 |
|
trifluoperazine |
1 |
|
waist circumference |
1 |
|
weight gain |
1 |
|
young adult |
1 |
|
ziprasidone |
1 |
